Vivos Therapeutics (NASDAQ:VVOS) Issues Earnings Results

Vivos Therapeutics (NASDAQ:VVOS) announced its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.01, FiscalAI reports. The firm had revenue of $6.78 million during the quarter, compared to analysts’ expectations of $4.49 million. Vivos Therapeutics had a negative return on equity of 232.76% and a negative net margin of 99.49%.

Vivos Therapeutics Price Performance

Shares of VVOS stock traded down $0.11 on Wednesday, reaching $2.36. The company had a trading volume of 62,825 shares, compared to its average volume of 360,140. The business’s 50-day moving average is $2.97 and its 200 day moving average is $3.52. Vivos Therapeutics has a one year low of $1.98 and a one year high of $7.95. The company has a quick ratio of 1.05, a current ratio of 1.05 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $17.71 million, a PE ratio of -1.40 and a beta of 6.88.

Hedge Funds Weigh In On Vivos Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in VVOS. XTX Topco Ltd acquired a new stake in Vivos Therapeutics in the second quarter valued at approximately $65,000. B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics during the second quarter worth $220,000. Finally, Connective Capital Management LLC bought a new position in shares of Vivos Therapeutics in the 3rd quarter valued at $620,000. Institutional investors own 26.35% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on VVOS shares. HC Wainwright initiated coverage on Vivos Therapeutics in a report on Monday. They set a “buy” rating and a $7.00 target price on the stock. Zacks Research downgraded shares of Vivos Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 31st. Ascendiant Capital Markets boosted their target price on shares of Vivos Therapeutics from $6.20 to $6.50 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Vivos Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, August 10th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $5.25.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.